A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial

References

• Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 2007; 82: 446–452.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007; 63: 245–256.
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 2489–2495.
   PubMed Web of Science ®Google Scholar
• Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005; 18: 57–68.
   PubMed Web of Science ®Google Scholar
• Kim JM, Ko YH, Lee SS, et al. WHO classification of malignant lymphomas in Korea: Report of the Third Nationwide Study. Korean J Pathol 2011; 45: 254–260.
   Web of Science ®Google Scholar
• Kim S, Shin DW, Yang HK, et al. Public perceptions on cancer incidence and survival: a Nation-wide Survey in Korea. Cancer Res Treat 2015. [Epub ahead of print]. doi: 10.4143/crt.2014.369.
   Google Scholar
• Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857–877.
   PubMed Web of Science ®Google Scholar
• Zucca E, Stathis A, Bertoni F. The management of nongastric MALT lymphomas. Oncology (Williston Park) 2014; 28: 86–93.
   PubMed Web of Science ®Google Scholar
• Raderer M, Wohrer S, Bartsch R, et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 8442–8446.
   PubMed Web of Science ®Google Scholar
• Alinari L, Musuraca G, Tani M, et al. Value of oxaliplatin treatment in heavily pretreated patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 1437–1440.
   PubMed Web of Science ®Google Scholar
• Oki Y, McLaughlin P, Pro B, et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 2005; 104: 781–787.
   PubMed Web of Science ®Google Scholar
• Sym SJ, Lee DH, Kang HJ, et al. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 2009; 64: 27–33.
   PubMed Web of Science ®Google Scholar
• Machover D, Delmas-Marsalet B, Misra SC, et al. Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. Biomed Pharmacother 2010; 64: 83–87.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
   PubMed Web of Science ®Google Scholar
• Simon R. How large should a phase II trial of a new drug be? Cancer Treat Rep 1987; 71: 1079–1085.
   PubMedGoogle Scholar
• Kiesewetter B, Ferreri AJ, Raderer M. Chemoimmunotherapy for mucosa-associated lymphoid tissue-type lymphoma: a review of the literature. Oncologist 2015; 20: 915–925.
   PubMed Web of Science ®Google Scholar
• Levy M, Copie-Bergman C, Amiot A, et al. Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study. Leuk Lymphoma 2013; 54: 940–944.
   PubMed Web of Science ®Google Scholar
• Levy M, Copie-Bergman C, Molinier-Frenkel V, et al. Treatment of t(11;18)-positive gastric mucosa-associated lymphoid tissue lymphoma with rituximab and chlorambucil: clinical, histological, and molecular follow-up. Leuk Lymphoma 2010; 51: 284–290.
   PubMed Web of Science ®Google Scholar
• Kiesewetter B, Mayerhoefer ME, Lukas J, et al. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Ann Hematol 2014; 93: 249–253.
   PubMed Web of Science ®Google Scholar
• Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol 2012; 91: 543–551.
   PubMed Web of Science ®Google Scholar
• Oh SY, Kim WS, Kim SJ, et al. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol 2009; 84: 826–829.
   PubMed Web of Science ®Google Scholar
• Oh SY, Kim WS, Lee DH, et al. Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs 2010; 28: 171–177.
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295–3301.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Dutia M, Chee K, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol 2014; 165: 375–381.
   PubMed Web of Science ®Google Scholar
• Ahmadi T, Chong EA, Gordon A, et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2014; 120: 222–228.
   PubMed Web of Science ®Google Scholar
• Conconi A, Raderer M, Franceschetti S, et al. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group. Br J Haematol 2014; 166: 69–76.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Takayama N, Aisa Y, et al. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study. Int J Hematol 2015; 101: 554–562.
   PubMed Web of Science ®Google Scholar
• Ogura M, Ando K, Suzuki T, et al. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Br J Haematol 2014; 165: 768–776.
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008–1018.
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123: 3406–3413.
   PubMed Web of Science ®Google Scholar